Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Graft vs Host Disease | 103 | 2024 | 3025 | 8.730 |
Why?
|
Hematopoietic Stem Cell Transplantation | 120 | 2024 | 5666 | 6.960 |
Why?
|
Transplantation Conditioning | 53 | 2024 | 1591 | 4.650 |
Why?
|
Hematologic Neoplasms | 29 | 2018 | 1895 | 2.210 |
Why?
|
Interleukin-2 | 14 | 2023 | 1891 | 2.170 |
Why?
|
Transplantation, Homologous | 64 | 2024 | 4822 | 1.840 |
Why?
|
Myelodysplastic Syndromes | 19 | 2024 | 1393 | 1.790 |
Why?
|
T-Lymphocytes, Regulatory | 19 | 2022 | 3092 | 1.590 |
Why?
|
Leukemia, Myeloid, Acute | 23 | 2024 | 3610 | 1.500 |
Why?
|
Tacrolimus | 13 | 2023 | 736 | 1.340 |
Why?
|
Cord Blood Stem Cell Transplantation | 15 | 2019 | 305 | 1.260 |
Why?
|
Myeloablative Agonists | 13 | 2019 | 209 | 1.210 |
Why?
|
HLA Antigens | 8 | 2020 | 1331 | 1.140 |
Why?
|
Boronic Acids | 4 | 2014 | 915 | 1.000 |
Why?
|
Graft vs Tumor Effect | 2 | 2016 | 68 | 0.920 |
Why?
|
Pyrazines | 4 | 2014 | 1202 | 0.890 |
Why?
|
Transplantation, Autologous | 14 | 2024 | 2112 | 0.810 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2023 | 92 | 0.780 |
Why?
|
Killer Cells, Natural | 8 | 2024 | 2194 | 0.700 |
Why?
|
Recurrence | 26 | 2024 | 8457 | 0.690 |
Why?
|
Chronic Disease | 32 | 2024 | 9319 | 0.670 |
Why?
|
Photopheresis | 1 | 2019 | 35 | 0.640 |
Why?
|
Histocompatibility | 3 | 2015 | 319 | 0.620 |
Why?
|
Hepatic Veno-Occlusive Disease | 6 | 2022 | 220 | 0.600 |
Why?
|
Lymphoproliferative Disorders | 2 | 2020 | 531 | 0.600 |
Why?
|
Chromosomes, Human, Pair 11 | 6 | 1999 | 410 | 0.590 |
Why?
|
Stem Cell Transplantation | 6 | 2017 | 1600 | 0.590 |
Why?
|
Transplantation Chimera | 6 | 2024 | 594 | 0.580 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2023 | 614 | 0.580 |
Why?
|
Iron Overload | 5 | 2012 | 239 | 0.560 |
Why?
|
Bronchiolitis Obliterans | 6 | 2022 | 213 | 0.520 |
Why?
|
Methotrexate | 9 | 2019 | 1718 | 0.510 |
Why?
|
Survival Analysis | 27 | 2018 | 10088 | 0.510 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2016 | 307 | 0.500 |
Why?
|
Lymphocyte Transfusion | 1 | 2016 | 232 | 0.490 |
Why?
|
Cyclophosphamide | 7 | 2023 | 2219 | 0.490 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 6 | 2016 | 263 | 0.460 |
Why?
|
Humans | 178 | 2024 | 761222 | 0.440 |
Why?
|
Adult | 107 | 2024 | 221120 | 0.440 |
Why?
|
Histocompatibility Testing | 6 | 2015 | 716 | 0.430 |
Why?
|
Paneth Cells | 1 | 2013 | 98 | 0.420 |
Why?
|
Multiple Myeloma | 7 | 2024 | 5145 | 0.420 |
Why?
|
Vidarabine | 7 | 2021 | 336 | 0.420 |
Why?
|
Middle Aged | 103 | 2024 | 220858 | 0.400 |
Why?
|
Disease-Free Survival | 23 | 2018 | 6819 | 0.400 |
Why?
|
Azacitidine | 2 | 2024 | 336 | 0.390 |
Why?
|
Germinal Center | 3 | 2022 | 380 | 0.380 |
Why?
|
Busulfan | 5 | 2021 | 258 | 0.380 |
Why?
|
Aged | 82 | 2024 | 169292 | 0.380 |
Why?
|
CD8-Positive T-Lymphocytes | 11 | 2022 | 4574 | 0.370 |
Why?
|
Sirolimus | 7 | 2016 | 1540 | 0.360 |
Why?
|
Fetal Blood | 7 | 2016 | 1348 | 0.350 |
Why?
|
Hematopoietic Stem Cells | 2 | 2020 | 3390 | 0.340 |
Why?
|
Forkhead Transcription Factors | 3 | 2013 | 1613 | 0.330 |
Why?
|
Prednisone | 1 | 2014 | 1565 | 0.330 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2021 | 1640 | 0.330 |
Why?
|
Cytomegalovirus Infections | 4 | 2023 | 828 | 0.330 |
Why?
|
Living Donors | 2 | 2015 | 643 | 0.330 |
Why?
|
Graft vs Leukemia Effect | 3 | 2020 | 121 | 0.330 |
Why?
|
Receptors, KIR | 2 | 2024 | 110 | 0.330 |
Why?
|
Combined Modality Therapy | 5 | 2019 | 8519 | 0.320 |
Why?
|
Thrombotic Microangiopathies | 2 | 2022 | 123 | 0.320 |
Why?
|
Erythema | 1 | 2010 | 262 | 0.320 |
Why?
|
Hydroxamic Acids | 1 | 2012 | 479 | 0.320 |
Why?
|
Gastrointestinal Tract | 2 | 2020 | 834 | 0.310 |
Why?
|
Male | 94 | 2024 | 360703 | 0.310 |
Why?
|
CD4-Positive T-Lymphocytes | 10 | 2021 | 4373 | 0.310 |
Why?
|
Female | 100 | 2024 | 392552 | 0.300 |
Why?
|
Steroids | 6 | 2022 | 929 | 0.290 |
Why?
|
Pulmonary Edema | 1 | 2010 | 408 | 0.290 |
Why?
|
Neoplasm, Residual | 3 | 2024 | 1008 | 0.290 |
Why?
|
Lymphoma | 6 | 2016 | 1898 | 0.290 |
Why?
|
Homeostasis | 3 | 2013 | 3322 | 0.290 |
Why?
|
Immunosuppressive Agents | 11 | 2020 | 4190 | 0.280 |
Why?
|
Leukemia | 8 | 2016 | 1518 | 0.280 |
Why?
|
Young Adult | 43 | 2024 | 59222 | 0.270 |
Why?
|
Acute Disease | 10 | 2020 | 7226 | 0.260 |
Why?
|
Antineoplastic Agents | 10 | 2017 | 13632 | 0.260 |
Why?
|
Protease Inhibitors | 1 | 2009 | 752 | 0.260 |
Why?
|
B-Lymphocytes | 8 | 2022 | 4744 | 0.260 |
Why?
|
Retrospective Studies | 47 | 2024 | 80675 | 0.260 |
Why?
|
T-Lymphocytes, Helper-Inducer | 5 | 2019 | 976 | 0.240 |
Why?
|
T-Lymphocytes | 3 | 2020 | 10203 | 0.230 |
Why?
|
Antigens, CD34 | 2 | 2024 | 655 | 0.230 |
Why?
|
Lymphocyte Activation | 7 | 2022 | 5478 | 0.220 |
Why?
|
S Phase | 1 | 2005 | 423 | 0.220 |
Why?
|
Venous Thromboembolism | 1 | 2017 | 1869 | 0.220 |
Why?
|
G1 Phase | 1 | 2005 | 404 | 0.220 |
Why?
|
Sweet Syndrome | 1 | 2023 | 58 | 0.220 |
Why?
|
Dexamethasone | 3 | 2019 | 1945 | 0.220 |
Why?
|
B-Cell Activating Factor | 3 | 2014 | 115 | 0.220 |
Why?
|
Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 21 | 0.210 |
Why?
|
Fever | 1 | 2010 | 1618 | 0.210 |
Why?
|
fms-Like Tyrosine Kinase 3 | 2 | 2016 | 496 | 0.200 |
Why?
|
Lymphocyte Depletion | 2 | 2016 | 602 | 0.200 |
Why?
|
Remission Induction | 7 | 2019 | 2392 | 0.200 |
Why?
|
Single-Cell Analysis | 1 | 2013 | 2452 | 0.200 |
Why?
|
Lymphocyte Count | 4 | 2019 | 781 | 0.200 |
Why?
|
Primary Myelofibrosis | 1 | 2023 | 208 | 0.190 |
Why?
|
Graft Survival | 8 | 2014 | 3843 | 0.190 |
Why?
|
Hematologic Diseases | 2 | 2018 | 496 | 0.190 |
Why?
|
Treatment Outcome | 30 | 2020 | 64681 | 0.180 |
Why?
|
Tissue Donors | 8 | 2022 | 2335 | 0.180 |
Why?
|
Survival Rate | 15 | 2018 | 12728 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 2 | 2018 | 190 | 0.180 |
Why?
|
Opportunistic Infections | 1 | 2023 | 376 | 0.180 |
Why?
|
Leukemia, Myeloid | 3 | 2021 | 693 | 0.180 |
Why?
|
Caenorhabditis elegans | 3 | 2015 | 1453 | 0.170 |
Why?
|
Drug Resistance | 2 | 2019 | 1594 | 0.170 |
Why?
|
Cytomegalovirus | 2 | 2017 | 750 | 0.170 |
Why?
|
Leukemia, Experimental | 1 | 2020 | 225 | 0.170 |
Why?
|
Skin Diseases | 2 | 2019 | 1095 | 0.170 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 269 | 0.160 |
Why?
|
Interleukin-23 | 1 | 2021 | 201 | 0.160 |
Why?
|
BK Virus | 1 | 2020 | 120 | 0.160 |
Why?
|
Time Factors | 13 | 2019 | 39957 | 0.160 |
Why?
|
Receptors, CXCR5 | 2 | 2016 | 88 | 0.160 |
Why?
|
Immunologic Memory | 4 | 2024 | 1361 | 0.160 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2017 | 1549 | 0.160 |
Why?
|
Adolescent | 33 | 2024 | 88300 | 0.150 |
Why?
|
Blood Donors | 2 | 2011 | 345 | 0.150 |
Why?
|
Bone Marrow Transplantation | 4 | 2023 | 2692 | 0.150 |
Why?
|
Herpesvirus 4, Human | 2 | 2023 | 1076 | 0.150 |
Why?
|
Mycophenolic Acid | 2 | 2019 | 350 | 0.150 |
Why?
|
Treatment Failure | 1 | 2024 | 2643 | 0.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 11733 | 0.150 |
Why?
|
Tretinoin | 1 | 2021 | 517 | 0.150 |
Why?
|
Chromosome Deletion | 3 | 1998 | 1386 | 0.150 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2022 | 890 | 0.150 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2021 | 651 | 0.150 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2020 | 433 | 0.140 |
Why?
|
DNA, Neoplasm | 4 | 2016 | 1743 | 0.140 |
Why?
|
Antibodies | 3 | 2017 | 2415 | 0.140 |
Why?
|
Follow-Up Studies | 15 | 2016 | 39127 | 0.140 |
Why?
|
Genes, Tumor Suppressor | 2 | 1999 | 1057 | 0.140 |
Why?
|
Disease Progression | 7 | 2023 | 13511 | 0.140 |
Why?
|
alpha 1-Antitrypsin | 1 | 2018 | 167 | 0.140 |
Why?
|
Myeloproliferative Disorders | 3 | 2016 | 609 | 0.140 |
Why?
|
Microsatellite Repeats | 2 | 1997 | 782 | 0.140 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 883 | 0.140 |
Why?
|
Sulfonamides | 2 | 2024 | 1977 | 0.140 |
Why?
|
Prognosis | 15 | 2022 | 29688 | 0.140 |
Why?
|
Genetic Markers | 4 | 1999 | 2599 | 0.140 |
Why?
|
Cell Proliferation | 4 | 2019 | 10423 | 0.130 |
Why?
|
Cancer Vaccines | 3 | 2014 | 1038 | 0.130 |
Why?
|
Antibodies, Monoclonal | 6 | 2022 | 9187 | 0.130 |
Why?
|
Incidence | 8 | 2023 | 21366 | 0.130 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2017 | 1372 | 0.130 |
Why?
|
Tandem Repeat Sequences | 1 | 2016 | 180 | 0.130 |
Why?
|
Clinical Trials as Topic | 4 | 2018 | 8002 | 0.130 |
Why?
|
Blood Specimen Collection | 1 | 2016 | 238 | 0.120 |
Why?
|
Hodgkin Disease | 2 | 2017 | 1379 | 0.120 |
Why?
|
Adrenal Cortex Hormones | 3 | 2020 | 1878 | 0.120 |
Why?
|
Patient Selection | 2 | 2020 | 4246 | 0.120 |
Why?
|
Piperidines | 2 | 2021 | 1656 | 0.120 |
Why?
|
Aging | 3 | 2010 | 8702 | 0.120 |
Why?
|
Mediastinal Neoplasms | 1 | 2017 | 401 | 0.120 |
Why?
|
Chromosome Aberrations | 2 | 2015 | 1767 | 0.120 |
Why?
|
Transplantation Immunology | 3 | 2016 | 537 | 0.120 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 899 | 0.120 |
Why?
|
Gene Deletion | 2 | 2019 | 2658 | 0.120 |
Why?
|
Drug Interactions | 1 | 2019 | 1417 | 0.120 |
Why?
|
Platelet Count | 1 | 2017 | 782 | 0.110 |
Why?
|
rho-Associated Kinases | 1 | 2016 | 281 | 0.110 |
Why?
|
Niacinamide | 1 | 2016 | 413 | 0.110 |
Why?
|
Immunotherapy | 3 | 2023 | 4642 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 5 | 2021 | 6486 | 0.110 |
Why?
|
16,16-Dimethylprostaglandin E2 | 1 | 2013 | 22 | 0.110 |
Why?
|
Adoptive Transfer | 1 | 2016 | 823 | 0.110 |
Why?
|
Gamma Rays | 1 | 2015 | 318 | 0.110 |
Why?
|
Cohort Studies | 12 | 2018 | 41496 | 0.110 |
Why?
|
Ferritins | 4 | 2012 | 596 | 0.110 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2017 | 686 | 0.110 |
Why?
|
Antilymphocyte Serum | 2 | 2012 | 491 | 0.110 |
Why?
|
Antigens, Surface | 1 | 2017 | 1607 | 0.110 |
Why?
|
Age Factors | 10 | 2024 | 18384 | 0.110 |
Why?
|
Phenylurea Compounds | 1 | 2016 | 529 | 0.110 |
Why?
|
Small Molecule Libraries | 1 | 2018 | 731 | 0.110 |
Why?
|
Donor Selection | 1 | 2015 | 232 | 0.110 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2014 | 254 | 0.110 |
Why?
|
Polymerase Chain Reaction | 4 | 1997 | 6067 | 0.100 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 694 | 0.100 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2021 | 2820 | 0.100 |
Why?
|
Mice, Inbred BALB C | 5 | 2020 | 6200 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1086 | 0.100 |
Why?
|
Syndrome | 3 | 2018 | 3271 | 0.100 |
Why?
|
Limbic Encephalitis | 1 | 2012 | 36 | 0.100 |
Why?
|
Leukocytes, Mononuclear | 2 | 2016 | 1838 | 0.100 |
Why?
|
Graft Rejection | 2 | 2024 | 4481 | 0.100 |
Why?
|
Chelation Therapy | 1 | 2012 | 77 | 0.100 |
Why?
|
Prospective Studies | 14 | 2022 | 54437 | 0.100 |
Why?
|
Roseolovirus Infections | 1 | 2012 | 49 | 0.100 |
Why?
|
Mutation | 7 | 2020 | 30004 | 0.100 |
Why?
|
Topography, Medical | 1 | 2011 | 37 | 0.100 |
Why?
|
STAT3 Transcription Factor | 1 | 2016 | 872 | 0.100 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 1405 | 0.100 |
Why?
|
Herpesvirus 6, Human | 1 | 2012 | 96 | 0.100 |
Why?
|
Pyridones | 1 | 2017 | 809 | 0.090 |
Why?
|
Leukocyte Count | 2 | 2014 | 1597 | 0.090 |
Why?
|
Saccharomyces cerevisiae | 1 | 2022 | 2667 | 0.090 |
Why?
|
Iron Chelating Agents | 1 | 2012 | 141 | 0.090 |
Why?
|
Retinoblastoma Protein | 1 | 2015 | 671 | 0.090 |
Why?
|
Melphalan | 3 | 2019 | 420 | 0.090 |
Why?
|
T-Lymphocyte Subsets | 2 | 2016 | 1803 | 0.090 |
Why?
|
Lymphoma, B-Cell | 1 | 2017 | 938 | 0.090 |
Why?
|
STAT5 Transcription Factor | 3 | 2017 | 266 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1923 | 0.090 |
Why?
|
Transplantation, Isogeneic | 1 | 2010 | 249 | 0.090 |
Why?
|
International Cooperation | 2 | 2014 | 1423 | 0.090 |
Why?
|
Sezary Syndrome | 1 | 2011 | 80 | 0.090 |
Why?
|
Observation | 1 | 2011 | 310 | 0.090 |
Why?
|
Consensus | 2 | 2021 | 3134 | 0.080 |
Why?
|
Markov Chains | 1 | 2013 | 965 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5665 | 0.080 |
Why?
|
Transplants | 1 | 2011 | 206 | 0.080 |
Why?
|
National Institutes of Health (U.S.) | 3 | 2021 | 793 | 0.080 |
Why?
|
Lung Diseases | 1 | 2019 | 1910 | 0.080 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2011 | 125 | 0.080 |
Why?
|
Mycosis Fungoides | 1 | 2011 | 170 | 0.080 |
Why?
|
Transforming Growth Factor beta | 1 | 2017 | 1963 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3594 | 0.080 |
Why?
|
Animals | 19 | 2024 | 168089 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1052 | 0.080 |
Why?
|
Multiprotein Complexes | 1 | 2015 | 1112 | 0.080 |
Why?
|
Mice, Inbred C57BL | 8 | 2020 | 22128 | 0.080 |
Why?
|
Hypertriglyceridemia | 1 | 2011 | 292 | 0.080 |
Why?
|
Cryopreservation | 3 | 2021 | 728 | 0.080 |
Why?
|
Heterozygote | 1 | 1995 | 2778 | 0.080 |
Why?
|
Whole-Body Irradiation | 2 | 2019 | 432 | 0.070 |
Why?
|
B-Lymphocyte Subsets | 1 | 2009 | 238 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2024 | 4872 | 0.070 |
Why?
|
Proteins | 1 | 2022 | 5993 | 0.070 |
Why?
|
Quality of Life | 4 | 2022 | 13367 | 0.070 |
Why?
|
Child | 9 | 2023 | 80154 | 0.070 |
Why?
|
Hypolipidemic Agents | 1 | 2011 | 609 | 0.070 |
Why?
|
Viremia | 1 | 2010 | 707 | 0.070 |
Why?
|
Flow Cytometry | 4 | 2024 | 5871 | 0.070 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2010 | 447 | 0.070 |
Why?
|
Cell Cycle | 1 | 2015 | 2926 | 0.070 |
Why?
|
Lymphoma, Follicular | 1 | 2011 | 457 | 0.070 |
Why?
|
Risk Factors | 8 | 2018 | 74241 | 0.070 |
Why?
|
Telomerase | 1 | 2011 | 741 | 0.070 |
Why?
|
Immunity, Humoral | 1 | 2010 | 598 | 0.070 |
Why?
|
Mice | 11 | 2024 | 81330 | 0.070 |
Why?
|
Siblings | 1 | 2010 | 824 | 0.060 |
Why?
|
Leukocytes | 1 | 2014 | 2025 | 0.060 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2015 | 2426 | 0.060 |
Why?
|
Mice, Knockout | 5 | 2020 | 14392 | 0.060 |
Why?
|
Pyrimidines | 2 | 2015 | 3027 | 0.060 |
Why?
|
Survivors | 1 | 2016 | 2369 | 0.060 |
Why?
|
Parathyroid Hormone | 1 | 2012 | 1803 | 0.060 |
Why?
|
Proto-Oncogene Proteins | 2 | 2017 | 4513 | 0.060 |
Why?
|
Iron | 2 | 2012 | 1791 | 0.060 |
Why?
|
Haplotypes | 1 | 2011 | 2715 | 0.060 |
Why?
|
Immunologic Factors | 1 | 2014 | 1589 | 0.060 |
Why?
|
Blood Platelets | 2 | 2013 | 2477 | 0.060 |
Why?
|
Isoantibodies | 1 | 2009 | 675 | 0.060 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2007 | 880 | 0.060 |
Why?
|
Thymus Gland | 1 | 2010 | 1243 | 0.060 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2871 | 0.060 |
Why?
|
Mice, Mutant Strains | 2 | 2019 | 1751 | 0.060 |
Why?
|
RNA, Helminth | 1 | 2004 | 59 | 0.060 |
Why?
|
Hypercholesterolemia | 1 | 2011 | 1141 | 0.060 |
Why?
|
Recovery of Function | 1 | 2015 | 2981 | 0.060 |
Why?
|
Breast Neoplasms | 4 | 2010 | 20982 | 0.060 |
Why?
|
Immunophenotyping | 3 | 2016 | 1867 | 0.060 |
Why?
|
Risk | 3 | 2011 | 9616 | 0.060 |
Why?
|
Pyrazoles | 1 | 2014 | 2010 | 0.060 |
Why?
|
Immunoprecipitation | 2 | 2017 | 874 | 0.060 |
Why?
|
Risk Assessment | 3 | 2017 | 24022 | 0.050 |
Why?
|
Cytokines | 2 | 2016 | 7386 | 0.050 |
Why?
|
Decision Support Techniques | 1 | 2013 | 2004 | 0.050 |
Why?
|
Influenza Vaccines | 1 | 2010 | 767 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2015 | 10218 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2013 | 10756 | 0.050 |
Why?
|
Antigens, CD | 3 | 2022 | 4009 | 0.050 |
Why?
|
Immunotherapy, Adoptive | 2 | 2024 | 1468 | 0.050 |
Why?
|
Alleles | 3 | 2019 | 6857 | 0.050 |
Why?
|
Genome | 2 | 2004 | 1738 | 0.050 |
Why?
|
GPI-Linked Proteins | 1 | 2024 | 470 | 0.050 |
Why?
|
Adenine | 2 | 2021 | 986 | 0.050 |
Why?
|
Kidney | 1 | 2018 | 7033 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2023 | 9278 | 0.050 |
Why?
|
Fetal Proteins | 1 | 2022 | 98 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2019 | 2549 | 0.050 |
Why?
|
Bone Marrow | 2 | 2022 | 2911 | 0.050 |
Why?
|
Glucocorticoids | 1 | 2011 | 2159 | 0.050 |
Why?
|
Thalidomide | 1 | 2007 | 885 | 0.050 |
Why?
|
Macrophages | 1 | 2017 | 5755 | 0.050 |
Why?
|
Salvage Therapy | 1 | 2008 | 1264 | 0.050 |
Why?
|
Severity of Illness Index | 4 | 2020 | 15841 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2014 | 5103 | 0.050 |
Why?
|
Chromosome Mapping | 4 | 1999 | 4612 | 0.050 |
Why?
|
Repressor Proteins | 3 | 2017 | 2974 | 0.050 |
Why?
|
Disease Models, Animal | 5 | 2020 | 18222 | 0.050 |
Why?
|
Open Reading Frames | 1 | 2004 | 811 | 0.050 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2022 | 263 | 0.050 |
Why?
|
Mitochondria | 1 | 2014 | 3620 | 0.050 |
Why?
|
Polydeoxyribonucleotides | 1 | 2022 | 136 | 0.050 |
Why?
|
Forehead | 1 | 2021 | 75 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2015 | 12474 | 0.040 |
Why?
|
Aged, 80 and over | 3 | 2016 | 58952 | 0.040 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2022 | 897 | 0.040 |
Why?
|
Ohio | 1 | 2021 | 322 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2016 | 1331 | 0.040 |
Why?
|
Odds Ratio | 2 | 2014 | 9652 | 0.040 |
Why?
|
Influenza, Human | 1 | 2010 | 1521 | 0.040 |
Why?
|
Chromosomes, Artificial, Yeast | 1 | 1999 | 113 | 0.040 |
Why?
|
Immunity, Innate | 1 | 2011 | 3044 | 0.040 |
Why?
|
Antibodies, Viral | 1 | 2010 | 3149 | 0.040 |
Why?
|
Sarcoma, Experimental | 1 | 1999 | 116 | 0.040 |
Why?
|
Mass Spectrometry | 2 | 2017 | 2189 | 0.040 |
Why?
|
Registries | 1 | 2015 | 8246 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2017 | 1404 | 0.040 |
Why?
|
Cell Count | 2 | 2016 | 1831 | 0.040 |
Why?
|
DNA, Satellite | 2 | 1995 | 66 | 0.040 |
Why?
|
Models, Biological | 1 | 2015 | 9458 | 0.040 |
Why?
|
Enzyme Inhibitors | 2 | 2022 | 3702 | 0.040 |
Why?
|
Cytogenetic Analysis | 2 | 2010 | 270 | 0.040 |
Why?
|
Scleroderma, Localized | 1 | 2019 | 87 | 0.040 |
Why?
|
United States | 7 | 2021 | 72341 | 0.040 |
Why?
|
Gene Library | 2 | 2014 | 1054 | 0.040 |
Why?
|
Endothelium, Vascular | 1 | 2010 | 4420 | 0.040 |
Why?
|
Models, Statistical | 1 | 2012 | 5081 | 0.040 |
Why?
|
Gene Expression | 3 | 2016 | 7571 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2007 | 6304 | 0.040 |
Why?
|
Disease Management | 2 | 2020 | 2507 | 0.040 |
Why?
|
HSP70 Heat-Shock Proteins | 1 | 1999 | 396 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 1997 | 6919 | 0.030 |
Why?
|
Fibrosarcoma | 1 | 1999 | 308 | 0.030 |
Why?
|
Progesterone | 1 | 2021 | 742 | 0.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 3245 | 0.030 |
Why?
|
Lymphocyte Cooperation | 1 | 2016 | 112 | 0.030 |
Why?
|
Vaccination | 2 | 2022 | 3369 | 0.030 |
Why?
|
RNA Interference | 1 | 2004 | 2816 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2024 | 3593 | 0.030 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2016 | 221 | 0.030 |
Why?
|
Helicobacter pylori | 1 | 1999 | 382 | 0.030 |
Why?
|
Human Genome Project | 1 | 1996 | 200 | 0.030 |
Why?
|
Lymphopoiesis | 1 | 2016 | 133 | 0.030 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2016 | 152 | 0.030 |
Why?
|
Cyclin D | 1 | 2015 | 72 | 0.030 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2016 | 225 | 0.030 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2021 | 937 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2016 | 4739 | 0.030 |
Why?
|
Receptors, Interleukin-21 | 1 | 2014 | 32 | 0.030 |
Why?
|
Blotting, Southern | 1 | 1995 | 775 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 2017 | 602 | 0.030 |
Why?
|
Dioxygenases | 1 | 2017 | 346 | 0.030 |
Why?
|
Uterine Cervical Dysplasia | 1 | 1998 | 384 | 0.030 |
Why?
|
Mouth Diseases | 1 | 2016 | 240 | 0.030 |
Why?
|
Child, Preschool | 4 | 2023 | 42225 | 0.030 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1995 | 765 | 0.030 |
Why?
|
Recombination, Genetic | 1 | 1999 | 1518 | 0.030 |
Why?
|
Stomatitis | 1 | 2016 | 271 | 0.030 |
Why?
|
Neoplasm Staging | 2 | 2020 | 11119 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2024 | 16954 | 0.030 |
Why?
|
Cell Cycle Proteins | 1 | 2005 | 3446 | 0.030 |
Why?
|
Antigens, CD20 | 1 | 2014 | 199 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2016 | 850 | 0.030 |
Why?
|
Clone Cells | 1 | 2017 | 1668 | 0.030 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2016 | 629 | 0.030 |
Why?
|
Antibody Formation | 1 | 2017 | 1391 | 0.030 |
Why?
|
Pulmonary Fibrosis | 1 | 2017 | 505 | 0.030 |
Why?
|
Oxazines | 1 | 2015 | 349 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 1999 | 2509 | 0.030 |
Why?
|
Infusions, Subcutaneous | 1 | 2012 | 43 | 0.030 |
Why?
|
Plasma Cells | 1 | 2016 | 597 | 0.030 |
Why?
|
Mice, Nude | 1 | 1999 | 3606 | 0.030 |
Why?
|
Polymorphism, Genetic | 3 | 1999 | 4243 | 0.030 |
Why?
|
CD40 Ligand | 1 | 2014 | 524 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2011 | 12052 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2012 | 69 | 0.020 |
Why?
|
Bacteremia | 1 | 1999 | 978 | 0.020 |
Why?
|
Coculture Techniques | 1 | 2016 | 1334 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2018 | 1436 | 0.020 |
Why?
|
Death | 1 | 2016 | 677 | 0.020 |
Why?
|
Morpholines | 1 | 2015 | 581 | 0.020 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2015 | 348 | 0.020 |
Why?
|
Deferoxamine | 1 | 2012 | 155 | 0.020 |
Why?
|
K562 Cells | 1 | 2013 | 640 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2011 | 5809 | 0.020 |
Why?
|
Genetic Diseases, Inborn | 1 | 1996 | 603 | 0.020 |
Why?
|
Aminopyridines | 1 | 2015 | 573 | 0.020 |
Why?
|
Cell Separation | 1 | 2016 | 1721 | 0.020 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2015 | 559 | 0.020 |
Why?
|
Transfection | 1 | 1999 | 5748 | 0.020 |
Why?
|
Infant | 3 | 2023 | 36170 | 0.020 |
Why?
|
Interleukin-17 | 1 | 2017 | 913 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2015 | 2468 | 0.020 |
Why?
|
Neutrophils | 2 | 2016 | 3763 | 0.020 |
Why?
|
Base Sequence | 3 | 2015 | 12404 | 0.020 |
Why?
|
Karyotyping | 1 | 2012 | 1172 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 1602 | 0.020 |
Why?
|
Virus Activation | 1 | 2012 | 319 | 0.020 |
Why?
|
Neoplasm Invasiveness | 2 | 1995 | 3590 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2570 | 0.020 |
Why?
|
Immune Tolerance | 1 | 2019 | 2307 | 0.020 |
Why?
|
Spleen | 1 | 2016 | 2290 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2012 | 15637 | 0.020 |
Why?
|
Thrombomodulin | 1 | 2010 | 105 | 0.020 |
Why?
|
Antibody Specificity | 1 | 2011 | 1059 | 0.020 |
Why?
|
Carcinoma in Situ | 1 | 1995 | 791 | 0.020 |
Why?
|
Th17 Cells | 1 | 2016 | 794 | 0.020 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2009 | 95 | 0.020 |
Why?
|
Interleukins | 1 | 2014 | 782 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2016 | 18927 | 0.020 |
Why?
|
History, 21st Century | 1 | 2015 | 1567 | 0.020 |
Why?
|
Molecular Sequence Data | 3 | 2015 | 17598 | 0.020 |
Why?
|
Reoperation | 1 | 2019 | 4303 | 0.020 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2010 | 352 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4107 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2014 | 1967 | 0.020 |
Why?
|
Caenorhabditis elegans Proteins | 1 | 2015 | 870 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 2016 | 1967 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8837 | 0.020 |
Why?
|
Calcineurin | 1 | 2008 | 229 | 0.020 |
Why?
|
E-Selectin | 1 | 2010 | 577 | 0.020 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 1995 | 1084 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2015 | 1528 | 0.020 |
Why?
|
Macrocyclic Compounds | 1 | 2007 | 68 | 0.020 |
Why?
|
Receptors, Complement 3b | 1 | 2007 | 136 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2015 | 2635 | 0.020 |
Why?
|
Apoptosis | 2 | 2014 | 9478 | 0.020 |
Why?
|
Erythroblasts | 1 | 2007 | 142 | 0.020 |
Why?
|
Hematopoiesis | 1 | 2017 | 2049 | 0.020 |
Why?
|
Erythrocytes | 1 | 2016 | 2413 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2012 | 2217 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 1995 | 2913 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2016 | 2881 | 0.020 |
Why?
|
Phenotype | 1 | 2004 | 16575 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2017 | 2915 | 0.020 |
Why?
|
Carrier Proteins | 1 | 1999 | 4935 | 0.020 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2010 | 1128 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2012 | 961 | 0.020 |
Why?
|
von Willebrand Factor | 1 | 2010 | 677 | 0.020 |
Why?
|
Canada | 1 | 2011 | 2125 | 0.020 |
Why?
|
Phosphorylation | 1 | 2017 | 8300 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 3577 | 0.020 |
Why?
|
Liver | 2 | 2012 | 7512 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2015 | 4243 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2014 | 14610 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2014 | 22174 | 0.020 |
Why?
|
Myeloid Cells | 1 | 2010 | 822 | 0.020 |
Why?
|
Serologic Tests | 1 | 2007 | 381 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2813 | 0.010 |
Why?
|
Down-Regulation | 1 | 2011 | 2916 | 0.010 |
Why?
|
Albumins | 1 | 2007 | 575 | 0.010 |
Why?
|
Genetic Variation | 1 | 2019 | 6567 | 0.010 |
Why?
|
Rabbits | 1 | 2010 | 4750 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2012 | 6223 | 0.010 |
Why?
|
Pyridines | 1 | 2015 | 2872 | 0.010 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2009 | 1348 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2015 | 3691 | 0.010 |
Why?
|
Uterine Cervical Neoplasms | 1 | 1995 | 2019 | 0.010 |
Why?
|
Infant, Newborn | 2 | 2014 | 26200 | 0.010 |
Why?
|
Drug Combinations | 1 | 2008 | 2048 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 7965 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 2008 | 1664 | 0.010 |
Why?
|
Lymphocytes | 1 | 2010 | 2603 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8663 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2010 | 3155 | 0.010 |
Why?
|
Administration, Oral | 1 | 2009 | 4015 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2012 | 5250 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15920 | 0.010 |
Why?
|
HSC70 Heat-Shock Proteins | 1 | 1999 | 48 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2009 | 6504 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2017 | 9567 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 1999 | 6506 | 0.010 |
Why?
|
Myocardium | 1 | 2012 | 4746 | 0.010 |
Why?
|
Pilot Projects | 1 | 2012 | 8642 | 0.010 |
Why?
|
Data Collection | 1 | 2008 | 3320 | 0.010 |
Why?
|
Papillomavirus E7 Proteins | 1 | 1998 | 109 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10516 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9417 | 0.010 |
Why?
|
Lung | 1 | 2016 | 9979 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2010 | 3552 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2009 | 4537 | 0.010 |
Why?
|
Oncogene Proteins, Viral | 1 | 1998 | 340 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2014 | 20118 | 0.010 |
Why?
|
Loss of Heterozygosity | 1 | 1998 | 662 | 0.010 |
Why?
|
Boston | 1 | 2008 | 9327 | 0.010 |
Why?
|
Sex Factors | 1 | 2009 | 10553 | 0.010 |
Why?
|
Adenosine Triphosphatases | 1 | 1999 | 833 | 0.010 |
Why?
|
DNA, Bacterial | 1 | 1999 | 1470 | 0.010 |
Why?
|
Neoplasms | 2 | 2009 | 22142 | 0.010 |
Why?
|
Length of Stay | 1 | 2008 | 6417 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2012 | 36415 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2007 | 15308 | 0.010 |
Why?
|
DNA Primers | 1 | 1995 | 2814 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2011 | 26072 | 0.010 |
Why?
|
Genotype | 1 | 2004 | 12985 | 0.010 |
Why?
|
Signal Transduction | 1 | 2013 | 23419 | 0.010 |
Why?
|
Papillomaviridae | 1 | 1995 | 1120 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1999 | 13402 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2004 | 11855 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 2011 | 15521 | 0.000 |
Why?
|
Carcinoma, Squamous Cell | 1 | 1995 | 4021 | 0.000 |
Why?
|
Adenocarcinoma | 1 | 1995 | 6341 | 0.000 |
Why?
|